Covista (CVSA) shares drew attention after the company announced a collaboration with Advocate Health to expand nursing education through Chamberlain University, offering scholarships, clinical placements and loan repayment support for future nurses.

Alongside the Advocate Health collaboration, Covista’s recent news flow has arrived during a period where the share price is up 18.55% year to date and 7.46% over 90 days, while the 3 year total shareholder return of about 2.6x suggests earlier investors have already seen very substantial gains. This hints that near term momentum is building off a longer term rerating.

If this kind of education and healthcare theme interests you, it could be worth widening the lens and checking out the Simply Wall St screener for 41 healthcare AI stocks

With Covista trading at $123.85 and sitting at roughly a 64% discount to one intrinsic value estimate and about 26% below the average analyst price target, investors now face a key question: is this a genuine opportunity, or is the market already baking in future growth?

Most Popular Narrative: 19.2% Undervalued

With Covista last closing at $123.85 versus a widely followed fair value narrative of $153.25, the current price sits well below that storyline and puts the underlying assumptions in focus.

Persistent health care workforce shortages in nursing, medicine and behavioral health create a structural need for large scale training capacity, which can support sustained demand for Covista's programs and underpin revenue growth.

Want to see what this shortage driven thesis really implies for Covista? The narrative leans on measured revenue expansion, firmer margins and a future earnings base that assumes disciplined capital allocation and a moderate valuation multiple. Curious which specific forecasts need to hold for that $153.25 figure to stack up?

Result: Fair Value of $153.25 (UNDERVALUED)

However, this Covista thesis still faces pressure if healthcare worker shortages ease faster than expected or if tighter student lending rules start to weigh on enrollment.

Another View: What Covista's P/E Is Telling You

The first narrative flags Covista as undervalued, but the current P/E of 16.9x paints a more mixed picture. It sits slightly above both direct peers at 16.3x and the wider US Consumer Services group at 16.4x, yet below an estimated fair ratio of 21x.

In simple terms, the market is already paying a small premium versus peers, while still leaving a gap to that higher fair ratio level. For investors, that combination can signal room for upside if the story plays out, but also less of a safety cushion if forecasts disappoint.

Next Steps

Given the mixed sentiment around Covista so far, it makes sense to look closely at the underlying numbers and assumptions yourself. To weigh up both sides of the story quickly, including at least 1 risk and 1 reward that investors are focused on, start with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Covista?

If Covista has caught your attention, do not stop there. Use the Simply Wall St Screener to quickly scan other potential opportunities that might fit your approach.

• Target regular income by reviewing companies with robust payouts and higher yields via the 9 dividend fortresses.
• Hunt for quality at a discount by assessing companies that look attractively priced on fundamentals using the 42 high quality undervalued stocks.
• Prioritise resilience by focusing on companies that score well on financial strength and stability through the 70 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.